Securities Lending Top 10 Earning Equities

DataLend presents its top 10 earnings equities for December 8, 2014. This list is built on DataLend’s universe of more than 42,000 securities on loan.

Methodology: We scan our universe of more than 42,000 securities on loan to find those securities with the most expensive financing positions in the U.S., U.K., Europe and Asia. Financing costs are determined by taking the total on-loan value of a security and multiplying it by the volume-weighted average fees to borrow that security, then converting the product of those numbers to a dollar value. We then sort the most expensive securities to finance in the securities lending market in descending order.

US

Utilization

1 AMTRUST FINANCIAL SERVICES 93.25%
2 GOPRO CL A 98.49%
3 MYRIAD GENETICS 89.10%
4 BURGER KING WORLDWIDE 92.53%
5 LINDSAY 85.39%
6 INVENSENSE 95.55%
7 3D SYSTEMS 90.23%
8 MOBILEYE 94.02%
9 DIAMOND OFFSHORE DRILLING 89.86%
10 SANDERSON FARMS 91.51%

UK

Utilization

1 SAINSBURYJ 73.38%
2 MONITISE 58.99%
3 LONMIN 68.66%
4 QUINDELL 91.00%
5 ASHMORE GROUP 62.98%
6 JSCJSC VTB BANK GDR 46.12%
7 GULF KEYSTONE PETROLEUM 94.01%
8 ASOS 67.77%
9 NANOCO GROUP 76.17%
10 WITAN INVESTMENT TRUST CF 79.37%

Europe

Utilization

1 GEMALTO (NL) 80.86%
2 SAINSBURYJ (GB) 73.38%
3 TOTAL (FR) 40.43%
4 BOLLORE (FR) 84.94%
5 SUEDZUCKER MANNHEIM OCHSENFURT (DE) 80.28%
6 TRANSOCEAN (CH) 85.79%
7 FIAT CHRYSLER AUTOMOBILES (IT) 56.05%
8 GEMALTO (FR) 90.35%
9 TGS NOPEC GEOPHYSICAL (NO) 82.50%
10 COMPAGNIE GENERALE GEOPHYSIQUE (FR) 65.99%

Far East/Australia Pacific

Utilization

1 HANERGY TFP (HK) 85.35%
2 EVERGRANDE (HK) 84.70%
3 MIXI (JP) 85.53%
4 CELLTRION (KR) 67.50%
5 ANHUI CONCH H (HK) 76.52%
6 PRADA (HK) 85.42%
7 SANRIO (JP) 82.24%
8 DAUM KAKAO (KR) 53.35%
9 GREE (JP) 84.98%
10 ANHUI CONCH H (HK) 70.19%

Click here for more information about DataLend’s key features.


THE INFORMATION CONTAINED HEREIN IS PROPRIETARY TO EQUILEND; MAY NOT BE COPIED OR DISTRIBUTED WITHOUT THE EXPRESS CONSENT OF EQUILEND; SHALL NOT CONSTITUTE INVESTMENT ADVICE BY EQUILEND, OR ANY REPRESENTATIVE THEREOF; IS NOT WARRANTED TO BE ACCURATE, COMPLETE OR TIMELY; IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY; IS NOT INTENDED FOR TRADING PURPOSES; AND SHOULD NOT BE CONSTRUED AS EQUILEND MAKING FORECASTS, PROJECTING RETURNS OR RECOMMENDING ANY PARTICULAR COURSE OF ACTION. NEITHER EQUILEND NOR ANY REPRESENTATIVE THEREOF SHALL BE AN ADVISOR OR A FIDUCIARY OF A VISITOR TO THIS WEBSITE. EQUILEND IS NOT RESPONSIBLE OR LIABLE IN ANY WAY TO THE READER OR VISITOR, OR TO ANY PERSON, FIRM OR CORPORATION FOR ANY DAMAGES OR LOSSES ARISING FROM ANY USE OF THE INFORMATION CONTAINED HEREIN. IN CONSIDERING THE INFORMATION CONTAINED HEREIN, A VISITOR TO THIS WEBSITE DOES SO SOLELY IN RELIANCE ON THE VISITOR’S OWN JUDGMENT. PAST PERFORMANCE IS NO GUARANTEE OF FUTURE PERFORMANCE.

Related Posts

Previous Post
Part II: The Fed releases rules on capital for GSIBs, includes extra requirements for securities financing trades
Next Post
Basel Committee: Net Stable Funding Ratio disclosure standards – consultative document

Fill out this field
Fill out this field
Please enter a valid email address.

X

Reset password

Create an account